Media Center

Tabuk Pharmaceuticals Announces Exclusive Partnership with Polaris Pharmaceuticals to introduce ADI-PEG20, an innovative First in class arginine degradation platform for hard-to-treat cancers in the Kingdom of Saudi Arabia and GCC Region.

Tabuk Pharmaceuticals Expands Strategic Partnership with HK inno.N to Include Additional MENA Markets for K-CAB® (Tegoprazan)

Tabuk Pharmaceuticals Announces Exclusive Licensing Partnership with Hanmi to Introduce Innovative Value-Added Medicines in the Kingdom of Saudi Arabia and MENA Region

Biocon Limited partners with Tabuk Pharmaceuticals to commercialise its Glucagon-like peptide-1 (GLP -1) products in the Middle East region.

Formosa Pharmaceuticals Announces Exclusive Licensing Agreement with Tabuk Pharmaceuticals, for the Commercialization of Clobetasol Propionate Ophthalmic Suspension, a Novel Medicine for the Treatment of Inflammation and Pain Following Ocular Surgery

Tabuk Pharmaceuticals and Globalpharma Sign an Agreement to Locally manufacture Key Pharmaceutical products in UAE.

Tabuk Pharmaceuticals Partners with Bio-Thera Solutions forRights to Manufacture and Commercialize BAT2206,a Stelara® (Ustekinumab) Biosimilar in Saudi Arabia

TABUK AND HK INNO.N PARTNER TO BRING K-CAB® (TEGOPRAZAN) AN INNOVATIVE MEDICINE TO THE MENA REGION.